HCPCS Codes for Medical care

  • A2001

    Innovamatrix ac, per square centimeter
  • A2002

    Mirragen advanced wound matrix, per square centimeter
  • A2004

    Xcellistem, 1 mg
  • A2005

    Microlyte matrix, per square centimeter
  • A2006

    Novosorb synpath dermal matrix, per square centimeter
  • A2007

    Restrata, per square centimeter
  • A2008

    Theragenesis, per square centimeter
  • A2009

    Symphony, per square centimeter
  • A2010

    Apis, per square centimeter
  • A2011

    Supra sdrm, per square centimeter
  • A2012

    Suprathel, per square centimeter
  • A2013

    Innovamatrix fs, per square centimeter
  • A4100

    Skin substitute, fda cleared as a device, not otherwise specified
  • A4216

    Sterile water, saline and/or dextrose, diluent/flush, 10 ml
  • A4217

    Sterile water/saline, 500 ml
  • A4218

    Sterile saline or water, metered dose dispenser, 10 ml
  • A9581

    Injection, gadoxetate disodium, 1 ml
  • C8957

    Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump
  • C9094

    Inj, sutimlimab-jome, 10 mg
  • C9095

    Inj, tebentafusp-tebn, 1 mcg
  • C9096

    Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
  • C9097

    Inj, faricimab-svoa, 0.1 mg
  • C9098

    Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
  • C9121

    Injection, argatroban, per 5 mg
  • C9132

    Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity
  • C9248

    Injection, clevidipine butyrate, 1 mg
  • C9285

    Lidocaine 70 mg/tetracaine 70 mg, per patch
  • C9290

    Injection, bupivacaine liposome, 1 mg
  • C9293

    Injection, glucarpidase, 10 units
  • C9399

    Unclassified drugs or biologicals
  • C9460

    Injection, cangrelor, 1 mg
  • C9738

    Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure)
  • C9757

    Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar
  • C9800

    Dermal injection procedure(s) for facial lipodystrophy syndrome (lds) and provision of radiesse or sculptra dermal filler, including all items and supplies
  • C9898

    Radiolabeled product provided during a hospital inpatient stay
  • C9899

    Implanted prosthetic device, payable only for inpatients who do not have inpatient coverage
  • G0010

    Administration of hepatitis b vaccine
  • G0028

    Documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason)
  • G0029

    Tobacco screening not performed or tobacco cessation intervention not provided on the date of the encounter or within the previous 12 months, reason not otherwise specified
  • G0030

    Patient screened for tobacco use and received tobacco cessation intervention on the date of the encounter or within the previous 12 months (counseling, pharmacotherapy, or both), if identified as a tobacco user
  • G0031

    Palliative care services given to patient any time during the measurement period
  • G0032

    Two or more antipsychotic prescriptions ordered for patients who had a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder on or between january 1 of the year prior to the measurement period and the index prescription start date (ipsd) for antipsychotics
  • G0033

    Two or more benzodiazepine prescriptions ordered for patients who had a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between january 1 of the year prior to the measurement period and the ipsd for benzodiazepines
  • G0034

    Patients receiving palliative care during the measurement period
  • G0035

    Patient has any emergency department encounter during the performance period with place of service indicator 23
  • G0036

    Patient or care partner decline assessment
  • G0037

    On date of encounter, patient is not able to participate in assessment or screening, including non-verbal patients, delirious, severely aphasic, severely developmentally delayed, severe visual or hearing impairment and for those patients, no knowledgeable informant available
  • G0038

    Clinician determines patient does not require referral
  • G0039

    Patient not referred, reason not otherwise specified
  • G0040

    Patient already receiving physical/occupational/speech/recreational therapy during the measurement period